{"id":"myeloma-immunoglobulin-idiotype-vaccine-klh","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL4650424","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine is personalized for each patient, using their myeloma's unique immunoglobulin idiotype conjugated to keyhole limpet hemocyanin (KLH) as an immunogenic carrier. This approach stimulates both cellular and humoral immune responses against the patient's own malignant plasma cells. By targeting the idiotype—a tumor-associated antigen unique to each patient's myeloma—the vaccine aims to induce durable anti-tumor immunity while minimizing off-target effects.","oneSentence":"This vaccine trains the immune system to recognize and attack cancer cells by targeting the unique protein signature (idiotype) present on individual myeloma tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:23.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (personalized idiotype vaccine)"}]},"trialDetails":[{"nctId":"NCT00019097","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-07","conditions":"Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT01426828","phase":"PHASE2","title":"Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-08","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00002787","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium","startDate":"1996-03","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":22},{"nctId":"NCT00006184","phase":"PHASE2","title":"Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-02-08","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00988312","phase":"PHASE1","title":"Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma","status":"COMPLETED","sponsor":"University Hospital Carl Gustav Carus","startDate":"2002-03","conditions":"Multiple Myeloma, Plasmocytoma","enrollment":9},{"nctId":"NCT00001561","phase":"PHASE3","title":"Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-11","conditions":"Graft vs Host Disease, Multiple Myeloma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Myeloma Immunoglobulin Idiotype Vaccine-KLH","genericName":"Myeloma Immunoglobulin Idiotype Vaccine-KLH","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This vaccine trains the immune system to recognize and attack cancer cells by targeting the unique protein signature (idiotype) present on individual myeloma tumors. Used for Multiple myeloma (personalized idiotype vaccine).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}